Breaking New Ground: Alector Secures $70 Million in Series C Funding for Immuno-Neurology Innovation

Alector, an innovative biotechnology firm based in South San Francisco, is thrilled to announce the successful closing of a $70 million funding round that will accelerate our mission to combat neurodegeneration and cancer through the groundbreaking field of immuno-neurology. Since our inception in 2013, we have set ourselves apart by focusing on harnessing the body's own immune system to fight these devastating diseases. Our diverse portfolio of programs, currently in various stages of clinical trials, reflects our commitment to addressing some of the most pressing challenges in neuroscience and oncology. The newly raised capital will be strategically allocated to advance our clinical programs and to expand our research initiatives, enabling us to bring innovative therapies to patients more rapidly. The support from our investors not only underscores the confidence in our mission but also empowers us to continue our bold pursuit of redefining immunotherapy. As we work tirelessly to push the boundaries of what’s possible, we remain dedicated to paving new paths in biotechnology that align with our vision of a future free from neurodegenerative diseases and cancer. We invite the community to join us on this transformative journey as we strive to make significant strides in medical science for the betterment of humanity.